Urokinase inhibitors

Details Urokinase inhibitors Urokinase inhibitors

1998-09-18

2010-06-29

Bernhardt, Emily (Department: 1624)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C514S330000, C544S388000, C546S213000, C546S226000

Reexamination Certificate

active

07745441

ABSTRACT:
New urokinase inhibitors having a triisopropylphenylsulfonyl residue as an Nα-substituent for 3-amidinophenylalanine are provided. The introduction of the triisopropylphenylsulfonyl residue greatly increases the affinity of the compounds to urokinase and, thereby, increases their inhibitory activity against urokinase. These urokinase inhibitors are useful in determining the role of urokinase and urokinase receptor in various diseases, particularly in tumor propagation and metastasis. Methods of treating tumors and a pharmaceutical composition are also provided.

REFERENCES:
patent: 5607937 (1997-03-01), Stuerzebecher et al.
patent: 6624169 (2003-09-01), Wilhelm et al.
patent: 6680320 (2004-01-01), Wilhelm et al.
patent: 7342018 (2008-03-01), Wilhelm et al.
patent: 2003/0013723 (2003-01-01), Wilhelm et al.
patent: 689611 (1999-07-01), None
patent: 00/04954 (2000-02-01), None
Plattner,Annual Reports in Medicinal Chemistry, vol. 34,pp. 121-128 (1999).
Andreasen et al. Int. J.Cancer vol. 72, pp. 1-22 (1997).
Renatus et al. J.Med. Chem. vol. 41, pp. 5445-5456 (Dec. 1998).
Sturzebecher et al. Bioorganic & Medicinal Chemistry Letters vol. 9, pp. 3147-3152 (1999).
Bernd Muehlenweg, Stefan Sperl, Viktor Magdolen, Manfred Schmitt & Nadia Harbeck, Interference with the urokinase plasminogen activator system: a promising therapy concept for solid tumours,Expert Opin. Biol. Ther. (2001) 1(4), 2001 © Ashley Publications Ltd. ISSN 1471-2598, pp. 683-691.
Fritz Jänicke, Anita Prechtl, Christoph Thomssen, Nadia Harbeck, Christoph Meisner, Michael Untch, C. G. J. Fred Sweep, Hans-Konrad Selbmann, Henner Graeff, Manfred Schmitt, Randomized Adjuvant Chemotherapy Trial in High-Risk, Lymph Node-Negative Breast Cancer Patients Identified by Urokinase-Type Plasminogen Activator and Plasminogen Activator Inhibitor Type 1,Journal of the National Cancer Institute, vol. 93, No. 12, Jun. 20, 2001, pp. 913-920.
Viktor Magdolen, Nuria Arroyo de Prada, Stefan Sperl, Bernd Muehlenweg, Thomas Luther, Olaf G. Wilhelm, Ulla Magdolen, Henner Graeff, Ute Reuning , and Manfred Schmitt, Natural and Synthetic Inhibitors of the Tumor-Associated Serine Protease Urokinase-Type Plasminogen Activator,Cellular Peptidases in Immune Functions and Diseases 2, 2000, Plenum Publishers, pp. 331-341.
M. Schmitt, O. G. Wilhelm, U. Reuning, A. Krüger, N. Harbeck, E. Lengyel, H. Graeff, B. Gänsbacher, H. Kessler, M. Bürgle, J. Stürzebecher, S. Sperl, V. Magdolen, The urokinase plasminogen activator system as a novel target for tumour therapy,Fibrinolysis&Proteolysis(2000)14(2/3), pp. 114-132.
Prefabloc—Series Synthetic Serine Proteinase Inhibitors [4904] (1997).
Pentapharm Product Catalog 1998.
Sturzebecher et al., 1997 Journal of Medical Chemistry 19(40): 3091-3099.
Markwardt et al., 1980 Thrombosis Research 17(3-4) 425-431.
Sturzebecher et al., 1997, Biological Chemistry Hoppe-Seyler 373(10): 1025-1030.
Wagner et al., 1981, Die Pharmazie 36(7): 467-470.
Sturzebecher et al., Die Pharmazie 36(7): 501-502, (1981).

Affiliated with

Also associated with

Rating

Urokinase inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Urokinase inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Urokinase inhibitors will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4178057